Navigation Links
Millennium Reports Outstanding Third-Quarter Results Driven by VELCADE(R) (Bortezomib) for Injection Sales

physicians prescribing VELCADE," said Christophe Bianchi, M.D., Executive Vice President, Commercial, Millennium. "The future of VELCADE is even more exciting as we look to expand into front-line multiple myeloma with several combinations that have the potential to deliver the strongest long- term survival for patients."

-- Phase III VISTA Trial in Front-Line Multiple Myeloma (MM) -- The

Company announced that the results of the large, randomized, Phase III

VISTA trial in patients with newly diagnosed MM showed that the therapy

of VELCADE, melphalan and prednisone demonstrated a highly

statistically significant improvement, compared with melphalan and

prednisone alone, across all efficacy endpoints, including time to

progression, complete remission rate, progression free survival and

overall survival. Side effects were manageable and included those seen

in previous VELCADE trials. Based on these positive data, the control

arm of the trial was stopped early to allow patients still being

treated with melphalan and prednisone to have VELCADE added to their

therapy. The Company now expects to file a supplementary new drug

application (sNDA) for use of VELCADE in patients with newly diagnosed

MM in December 2007.

-- Compendia Listing in Front-Line MM -- In October 2007, the national

compendia organization DrugPoints Systems included VELCADE as a

recommended therapy for use in newly diagnosed multiple myeloma


-- Label Expansion in MM -- In October 2007, the U.S. Food and Drug

Administration (FDA) granted approval for VELCADE use, without dose

adjustments, in patients with impaired kidney function, including those

requiring dialysis. Impaired kidney function is a common complication

related to MM, affecting approximately 30 percent of patients at


SOURCE Millennium Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
(Date:5/21/2015)... (PRWEB) May 21, 2015 Specialty ... audit and been admitted to BPA Worldwide as ... Worldwide will track audience data for Specialty Pharmacy ... , “By becoming a member of BPA ... to providing our clients with the most reliable, ...
(Date:5/21/2015)... May 21, 2015  Prima Biomed Ltd. (NASDAQ: ... striving to become a leader in the development of ... that the final CVac data from the Phase II ... trend for a clinically meaningful improvement in Overall Survival ... patients. In the group of second remission ...
(Date:5/21/2015)... 2015  The EveryLife Foundation for Rare Diseases ... Amy Klobuchar (D-MN) today for introducing ... Treatments, or OPEN ACT. Supported by ... this bipartisan legislation promises to rapidly bring hundreds ... disease patients by incentivizing drug makers to "repurpose" ...
(Date:5/21/2015)... W. R. Grace & Co. ... Worms, Germany has received good manufacturing practice (GMP) ... International Pharmaceutical Excipient Council (IPEC) Foundation. ... SYLOID® FP brand of pharmaceutical grade excipient silica ... Curtis Bay, Maryland (USA) and Sorocaba, Brazil locations. ...
Breaking Biology Technology:Specialty Pharmacy Times Joins BPA Worldwide 2Correction Continues after Big Move - BrokerBank Securities, Inc. 2Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2
... Ralph is one of the most successful entrepreneurs in the ... and CEO of Point One Personal Genetic Systems. , ,But ... in high-tech entrepreneurship is somehow related to his own efforts. ... been a lucky guy. , ,When asked to share the ...
... Center at University Research Park. Madison, Wis. ... on Tuesday that they have successfully secured an investment ... firm Wisconsin Investment Partners . The new funds ... well as financing animal testing of biotheraputic treatments. , ...
... culture of its people to the size of its ... dollars. The state ranks 40th among the 50 states ... far more money to Washington than they get back. ... programs, including Social Security and Medicare, and even lower ...
Cached Biology Technology:Ralph Kauten on how to raise angel financing 2Ralph Kauten on how to raise angel financing 3Ralph Kauten on how to raise angel financing 4ConjuGon lands $1 million angel investment 2Academic R&D helps bring federal bucks back to Wisconsin 2Academic R&D helps bring federal bucks back to Wisconsin 3
(Date:5/19/2015)... Research and Markets ( ... the  "Genetic Testing Market Outlook 2018"  report ... ,A recent report, Genetic Testing Market Outlook ... current and future genetic testing market. A ... principles and types are covered in this ...
(Date:5/11/2015)... May 11, 2015  Synaptics Incorporated (NASDAQ: ... solutions, today announced the appointment of Wajid ... Financial Officer, reporting to Rick Bergman , ... Chief Financial Officer, Kathleen Bayless , who ... Mr. Ali brings extensive financial management expertise ...
(Date:5/8/2015)... , May 8, 2015 Synaptics Inc. (NASDAQ: ... announced that members of the executive management team will present ... Annual Technology, Media and Telecom Conference Date: May 18, ... Boston, MA Cowen and ... Time: 2:45pm ET Location: The New York Palace Hotel, ...
Breaking Biology News(10 mins):Global Genetic Testing Market Outlook 2018 2Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2Synaptics to Present at Upcoming Investor Conferences 2
... warming is causing the worldwide declines of amphibians may ... biologists. The findings, which contradict two widely held views, ... toads and aid in their conservation. "We are ... event," said Peter Hudson, the Willaman professor of biology ...
... by the National Environment Research Council and led by ... and colleagues from Cambridge University and British Antarctic Survey ... week. The World Conference on Marine Biodiversity is ... The Queen,s research forms part of a decade-long ...
... -- Pollution by phosphorous and nitrogen isn,t just bad for ... researchers at Kansas State University, it,s also bad for Americans, ... basic as how much they spend on bottled water, said ... about what,s in the tap water, you might be shelling ...
Cached Biology News:Global warming link to amphibian declines in doubt 2Global warming link to amphibian declines in doubt 3Queen's University Belfast researchers trace octopuses' family tree 2K-State research: Freshwater pollution costs US at least $4.3 billion a year 2
ZBP-89 (S-15)...
S-100 alpha/beta chain (8B10)...
... Essentially sulfate-free, powder containing carbohydrate and ... Unit Definition: One unit will convert ... 6-phosphate to D -glucose 6-phosphate ... 25 C. Chem comp: ...
Biology Products: